Patents by Inventor Haiqun Tang

Haiqun Tang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METALLO-BETA-LACTAMASE INHIBITORS
    Publication number: 20160333021
    Abstract: The present invention relates to compounds of formula (I) that are metallo-?-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with ?-lactam antibiotics for overcoming resistance.
    Type: Application
    Filed: January 16, 2015
    Publication date: November 17, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Mihir Mandal, Haifeng Tang, Li Xiao, Jing Su, Guoqing Li, Shu-Wei Yang, Weidong Pan, Haiqun Tang, Reynalda DeJesus, Jacqueline Hicks, Matthew Lombardo, Hong Chu, William Hagmann, Alex Pasternak, Xin Gu, Jinlong Jiang, Shuzhi Dong, Fa-Xiang Ding, Clare London, Dipshikha Biswas, Katherine Young, David N. Hunter, Zhiqiang Zhao, Dexi Yang
  • INHIBITORS OF IRAK4 ACTIVITY
    Publication number: 20150274708
    Abstract: The present invention relates to inhibitors of IRAK4 of Formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Application
    Filed: October 3, 2013
    Publication date: October 1, 2015
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: W. Michael Seganish, Jennifer Hanisak, Guoqing Li, Rui Zhang, Haiqun Tang
  • SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
    Publication number: 20150057246
    Abstract: The present invention relates to novel Silyl-Containing Heterocyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, D and R2 are as defined herein. The present invention also relates to compositions comprising at least one Silyl-Containing Heterocyclic Compound, and methods of using the Silyl-Containing Heterocyclic Compounds for treating or preventing HCV infection in a patient.
    Type: Application
    Filed: September 11, 2012
    Publication date: February 26, 2015
    Inventors: Michael P. Dwyer, Kartik M. Keertikar, Qingbei Zeng, Robert D. Mazzola, JR., John P. Caldwell, Haiqun Tang, Anilkumar Gopinadhan Nair, Bandarpalle B. Shankar, Stuart B. Rosenblum, Joseph A. Kozlowski
  • Quinazolinone-type compounds as CRTH antagonists
    Patent number: 8927559
    Abstract: This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTH2 receptor.
    Type: Grant
    Filed: October 6, 2011
    Date of Patent: January 6, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Robert G. Aslanian, Christopher W. Boyce, Robert D. Mazzola, Jr., Brian A. McKittrick, Kevin D. McCormick, Anandan Palani, Jun Qin, Haiqun Tang, Dong Xiao, Younong Yu, John P. Caldwell, Elizabeth Helen Kelley, Hongjun Zhang, Phieng Siliphaivanh, Rachel N. MacCoss, Joey L. Methot, Jolicia Polivina Gauuan, Qin Jiang, Andrew J. Leyhane, Purakkattle Johny Biju, Li Dong, Xianhai Huang, Ning Shao, Wei Zhou, Pawan K. Dhondi, Ashwin U. Rao
  • SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
    Publication number: 20140378416
    Abstract: The present invention relates to novel Silyl-Containing Heterocyclic Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, D, E, F and L are as defined herein. The present invention also relates to compositions comprising at least one Silyl-Containing Heterocyclic Compound, and methods of using the Silyl-Containing Heterocyclic Compounds for treating or preventing HCV infection in a patient.
    Type: Application
    Filed: September 11, 2012
    Publication date: December 25, 2014
    Inventors: Michael P. Dwyer, Kartik M. Keertikar, Qingbei Zeng, Robert D. Mazzola, JR., Wensheng Yu, Haiqun Tang, Seong Heon Kim, Ling Tong, Stuart B. Rosenblum, Joseph A. Kozlowski, Anilkumar Gopinadhan Nair
  • Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
    Patent number: 8569521
    Abstract: This invention discloses novel gamma secretase inhibitors of the formula: R2 and R3, or R2 and R4, or R3 and R4, together with the atoms to which they are bound, can form a fused cycloalkyl or fused heterocycloalkyl ring. The cycloalkyl ring or the heterocycloalkyl ring can be optionally substituted with one or more substituents. One or more compounds of formula (I), or formulations comprising such compounds, may be useful, e.g. in treating Alzheimer's Disease.
    Type: Grant
    Filed: October 6, 2011
    Date of Patent: October 29, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Theodros Asberom, Thomas A. Bara, Chad E. Bennett, Duane A. Burnett, Mary Anne Caplen, John W. Clader, David J. Cole, Martin S. Domalski, Hubert B. Josien, Chad E. Knutson, Hongmei Li, Mark D. McBriar, Dmitri A. Pissarnitski, Li Qiang, Murali Rajagopalan, Thavalakulamgara K. Sasikumar, Jing Su, Haiqun Tang, Wen-Lian Wu, Ruo Xu, Zhiqiang Zhao
  • QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS
    Publication number: 20130210805
    Abstract: This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTH2 receptor.
    Type: Application
    Filed: October 6, 2011
    Publication date: August 15, 2013
    Inventors: Robert G. Aslanian, Christopher W. Boyce, Robert D. Mazzola, JR., Brian A. McKittrick, Kevin D. McCormick, Anandan Palani, Jun Qin, Haiqun Tang, Dong Xiao, Younong Yu, John P. Caldwell, Elizabeth Helen Kelley, Hongjun Zhang, Phieng Siliphaivanh, Rachel N. MacCoss, Joey L. Methot, Jolicia Polivina Gauuan, Qin Jiang, Andrew J. Leyhane, Johny Biju, Li Dong, Xian Huang, Ning Shao, Wei Zhou, Pawan K. Dhondi
  • BENZENESULFONYL-CHROMANE, THIOCHROMANE, TETRAHYDRONAPHTHALENE AND RELATED GAMMA SECRETASE INHIBITORS
    Publication number: 20120264736
    Abstract: This invention discloses novel gamma secretase inhibitors of the formula: R2 and R3, or R2 and R4, or R3 and R4, together with the atoms to which they are bound, can form a fused cycloalkyl or fused heterocycloalkyl ring. The cycloalkyl ring or the heterocycloalkyl ring can be optionally substituted with one or more substituents. One or more compounds of formula (I), or formulations comprising such compounds, may be useful, e.g. in treating Alzheimer's Disease.
    Type: Application
    Filed: October 6, 2011
    Publication date: October 18, 2012
    Applicant: Schering Corporation
    Inventors: Theodros Asberom, Thomas A. Bara, Chad E. Bennett, Duane A. Burnett, Mary Ann Caplen, John W. Clader, David J. Cole, Martin S. Domalski, Hubert B. Josien, Chad E. Knutson, Hongmei Li, Mark D. McBriar, Dmitri A. Pissarnitski, Li Qiang, Murali Rajagopalan, Thavalakulamgara K. Sasikumar, Jing Su, Haiqun Tang, Wen-Lian Wu, Ruo Xu, Zhiqiang Zhao
  • Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
    Patent number: 8067621
    Abstract: This invention discloses novel gamma secretase inhibitors of the formula: R2 and R3, or R2 and R4, or R3 and R4, together with the atoms to which they are bound, can form a fused cycloalkyl or fused heterocycloalkyl ring. The cycloalkyl ring or the heterocycloalkyl ring can be optionally substituted with one or more substitutents. One or more compounds of formula (I), or formulations comprising such compounds, may be useful, e.g. in treating Alzheimer's Disease.
    Type: Grant
    Filed: January 18, 2007
    Date of Patent: November 29, 2011
    Assignee: Schering Corporation
    Inventors: Theodros Asberom, Thomas A. Bara, Chad E. Bennett, Duane A. Burnett, Mary Ann Caplen, John W. Clader, David J. Cole, Martin S. Domalski, Hubert B. Josien, Chad E. Knutson, Hongmei Li, Mark D. McBriar, Dmitri A. Pissarnitski, Li Qiang, Murali Rajagopalan, Thavalakulamgara K. Sasikumar, Jing Su, Haiqun Tang, Wen-Lian Wu, Ruo Xu, Zhiqiang Zhao
  • NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20110152259
    Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).
    Type: Application
    Filed: February 24, 2011
    Publication date: June 23, 2011
    Inventors: Anandan Palani, Jing Su, Dong Xiao, Xianhai Huang, Ashwin U. Rao, Xiao Chen, Haiqun Tang, Jun Qin, Ying R. Huang, Robert G. Aslanian, Brain A. McKittrick, Syliva J. Degrado
  • NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20100227873
    Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).
    Type: Application
    Filed: April 30, 2010
    Publication date: September 9, 2010
    Inventors: Anandan Palani, Jing Su, Dong Xiao, Xianhai Huang, Ashwin U. Rao, Xiao Chen, Haiqun Tang, Jun Qin, Ying R. Huang, Robert G. Aslanian, Brian A. McKittrick, Syliva J. Degrado
  • Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
    Patent number: 7723342
    Abstract: A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome and dyslipidemia.
    Type: Grant
    Filed: May 11, 2006
    Date of Patent: May 25, 2010
    Assignee: Schering Corporation
    Inventors: Anandan Palani, Jing Su, Dong Xiao, Xianhai Huang, Ashwin U. Rao, Xiao Chen, Haiqun Tang, Jun Qin, Ying Huang, Robert G. Aslanian, Brian A. McKittrick
  • Heterocyclyls as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
    Patent number: 7361769
    Abstract: The present invention discloses compounds of formula I wherein m, n, p, R1, R2 and X, are herein defined, the compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
    Type: Grant
    Filed: July 14, 2005
    Date of Patent: April 22, 2008
    Assignee: Schering Corporation
    Inventors: Jing Su, Brian A. McKittrick, Haiqun Tang, Thavalakulamgara K. Sasikumar, Li Qiang
  • MCH antagonists for the treatment of obesity
    Patent number: 7348328
    Abstract: The present invention discloses compounds which, are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: March 25, 2008
    Assignee: Schering Corporation
    Inventors: John W. Clader, Anandan Palani, Ruo Xu, Mark D. McBriar, Jing Su, Haiqun Tang
  • NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20080019978
    Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).
    Type: Application
    Filed: June 29, 2007
    Publication date: January 24, 2008
    Inventors: Anandan Palani, Jing Su, Dong Xiao, Xianhai Huang, Ashwin Rao, Xiao Chen, Haiqun Tang, Jun Qin, Ying Huang, Robert Aslanian, Brian McKittrick, Sylvia Degrado
  • Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
    Publication number: 20070197581
    Abstract: This invention discloses novel gamma secretase inhibitors of the formula: R2 and R3, or R2 and R4, or R3 and R4, together with the atoms to which they are bound, can form a fused cycloalkyl or fused heterocycloalkyl ring. The cycloalkyl ring or the heterocycloalkyl ring can be optionally substituted with one or more substitutents. One or more compounds of formula (I), or formulations comprising such compounds, may be useful, e.g. in treating Alzheimer's Disease.
    Type: Application
    Filed: January 18, 2007
    Publication date: August 23, 2007
    Inventors: Theodros Asberom, Thomas Bara, Chad Bennett, Duane Burnett, Mary Ann Caplen, John Clader, David Cole, Martin Domalski, Hubert Josien, Chad Knutson, Hongmei Li, Mark McBriar, Dmitri Pissarnitski, Li Qiang, Murali Rajagopalan, Thavalakulamgara Sasikumar, Jing Su, Haiqun Tang, Wen-Lian Wu, Ruo Xu, Zhiqiang Zhao
  • Nitrogen-containing heterocyclic compounds and methods of use thereof
    Publication number: 20070066630
    Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: L is selected from the group consisting of: ?pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).
    Type: Application
    Filed: November 15, 2006
    Publication date: March 22, 2007
    Inventors: Anandan Palani, Jing Su, Dong Xiao, Xianhai Huang, Ashwin Rao, Xiao Chen, Haiqun Tang, Jun Qin, Ying Huang, Robert Aslanian, Brian McKittrick, Sylvia Degrado
  • Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
    Publication number: 20060264489
    Abstract: A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome and dyslipidemia.
    Type: Application
    Filed: May 11, 2006
    Publication date: November 23, 2006
    Inventors: Anandan Palani, Jing Su, Dong Xiao, Xianhai Huang, Ashwin Rao, Xiao Chen, Haiqun Tang, Jun Qin, Ying Huang, Robert Aslanian, Brian McKittrick
  • Novel heterocyclyls as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
    Publication number: 20060106031
    Abstract: The present invention discloses compounds of formula I wherein m, n, p, R1, R2 and X, are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
    Type: Application
    Filed: July 14, 2005
    Publication date: May 18, 2006
    Inventors: Jing Su, Brian McKittrick, Haiqun Tang, Thavalakulamgara Sasikumar, Li Qiang
  • MCH antagonists for the treatment of obesity
    Publication number: 20040122017
    Abstract: The present invention discloses compounds which, are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
    Type: Application
    Filed: December 3, 2002
    Publication date: June 24, 2004
    Applicant: Schering Corporation
    Inventors: John W. Clader, Anandan Palani, Ruo Xu, Mark D. McBriar, Jing Su, Haiqun Tang